Melissa A. Reimers

Washington University in St. Louis — United States

Medicine · Health Sciences

18h-index1.8kcitations118works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(47), Cancer Immunotherapy and Biomarkers(41), Bladder and Urothelial Cancer Treatments(25), Cancer Genomics and Diagnostics(22), Renal cell carcinoma treatment(20)

Publications118 total

22Final results of the phase 3 COSMIC-313 study comparing first-line cabozantinib plus nivolumab and ipilimumab with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma
The Oncologist·2025Open Access
18EXACT: a randomized phase II trial of XL092 (zanzalintinib) in combination with immunotherapy in patients who progress on adjuvant therapy in clear cell RCC [NCT06863311]
The Oncologist·2025Open Access
2682eTiP EXPLORE-RCC: A phase II study of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma (ccRCC)
Annals of Oncology·2025
3070MO Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
Annals of Oncology·2025
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC).
Journal of Clinical Oncology·2025
Structural classification of <i>FOXA1</i> alterations and their association with clinical outcomes and transcriptional profiles in prostate cancer patients.
Journal of Clinical Oncology·2025· 1 cited
A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY).
Journal of Clinical Oncology·2025
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Current Treatment Options in Oncology·2025· 9 citedOpen Access
Abstract 3258: Predicting genitourinary cancer tissue-of-origin using urine cell-free DNA fragmentomics and cell-free RNA
Cancer Research·2025
Abstract 6621: Multi-modal profiling reveals the role of somatic structural variations in renal cell carcinoma
Cancer Research·2025
IP14-01 GENOME-WIDE FRAGMENTOMICS AND COPY NUMBER PROFILING OF URINE CFDNA PREDICTS TUMOR ORIGIN IN GENITOURINARY CANCERS
The Journal of Urology·2025
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.
Journal of Clinical Oncology·2025· 12 cited
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
Journal of Clinical Oncology·2025· 9 cited
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
Journal of Clinical Oncology·2025· 1 cited
Preferred treatment regimens for rare genitourinary (GU) malignancies.
Journal of Clinical Oncology·2025· 1 cited
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.
Journal of Clinical Oncology·2025
A phase 1b study of cabozantinib and nivolumab with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings.
Journal of Clinical Oncology·2025
Predicting genitourinary cancer tissue-of-origin using urine cell-free DNA fragmentomic features
The Journal of Liquid Biopsy·2024· 1 citedOpen Access
Tumour evolution and microenvironment interactions in 2D and 3D space
Nature·2024· 102 citedOpen Access
Progress and Promise for Multicancer Early Detection Testing in Prostate Cancer
JCO Precision Oncology·2024
page 1 of 6Next →

Frequent Co-authors

Russell K. Pachynski(18), Eric H. Kim(10), Brian C. Baumann(9), Ajjai Alva(7), E Knoche(7), Marcin Cieślik(6), Jonathan Chou(6), Felix Y. Feng(6), Zachary L. Smith(6), Vivek Arora(6), Joel Picus(6), Arul M. Chinnaiyan(5), Cody Weimholt(5), Aadel A. Chaudhuri(5), Bruce J. Roth(5), Li Ding(4), Pradeep S. Chauhan(4), Peter K. Harris(4), Dhruv Bansal(4), Rana R. McKay(4)